ProductNum | picture | CAS No. | Name and description | Size | Formula | Quick order |
---|---|---|---|---|---|---|
GC31294-10mg |
|
139652-01-0 |
Sigma-LIGAND-1
|
0 | C27H33NO4 | |
GC31294-5mg |
|
139652-01-0 |
Sigma-LIGAND-1
|
0 | C27H33NO4 | |
GC31294-1mg |
|
139652-01-0 |
Sigma-LIGAND-1
|
0 | C27H33NO4 | |
GC31293-20mg |
|
168830-01-1 |
Heterocyclyl carbamate derivative 1
|
0 | C26H29N3O2 | |
GC31293-10mg |
|
168830-01-1 |
Heterocyclyl carbamate derivative 1
|
0 | C26H29N3O2 | |
GC31293-5mg |
|
168830-01-1 |
Heterocyclyl carbamate derivative 1
|
0 | C26H29N3O2 | |
GC31293-1mg |
|
168830-01-1 |
Heterocyclyl carbamate derivative 1
|
0 | C26H29N3O2 | |
GC31292-50mg |
|
845959-50-4 |
Mitoquinone mesylate (Mitoquinone methanesulfonate)
|
0 | C38H47O7PS | |
GC31292-25mg |
|
845959-50-4 |
Mitoquinone mesylate (Mitoquinone methanesulfonate)
|
0 | C38H47O7PS | |
GC31292-10mg |
|
845959-50-4 |
Mitoquinone mesylate (Mitoquinone methanesulfonate)
|
0 | C38H47O7PS | |
GC31292-5mg |
|
845959-50-4 |
Mitoquinone mesylate (Mitoquinone methanesulfonate)
|
0 | C38H47O7PS | |
GC31290-1g |
|
830-96-6 |
3-Indolepropionic acid
|
0 | C11H11NO2 | |
GC31289-20mg |
|
137315-05-0 |
Urinary Incontinence-Targeting Compound 1
|
0 | C9H13FN2O3S | |
GC31289-10mg |
|
137315-05-0 |
Urinary Incontinence-Targeting Compound 1
|
0 | C9H13FN2O3S | |
GC31289-5mg |
|
137315-05-0 |
Urinary Incontinence-Targeting Compound 1
|
0 | C9H13FN2O3S | |
GC31289-1mg |
|
137315-05-0 |
Urinary Incontinence-Targeting Compound 1
|
0 | C9H13FN2O3S | |
GC31288-10mg |
|
374538-23-5 |
Neuromuscular Disorder-Targeting Compound 1
|
0 | C15H25N3S | |
GC31288-5mg |
|
374538-23-5 |
Neuromuscular Disorder-Targeting Compound 1
|
0 | C15H25N3S | |
GC31288-1mg |
|
374538-23-5 |
Neuromuscular Disorder-Targeting Compound 1
|
0 | C15H25N3S | |
GC31287-20mg |
|
152886-85-6 |
U91356
|
0 | C13H17N3O | |